Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 189

1.

Development and Validation of an HPLC Method for Simultaneous Determination of Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol Hydrochloride in Pharmaceutical Formulations.

Chellini PR, Lages EB, Franco PH, Nogueira FH, César IC, Pianetti GA.

J AOAC Int. 2015 Sep-Oct;98(5):1234-9. doi: 10.5740/jaoacint.14-237.

PMID:
26525241
2.

Benefits of combined preventive therapy with co-trimoxazole and isoniazid in adults living with HIV: time to consider a fixed-dose, single tablet coformulation.

Harries AD, Lawn SD, Suthar AB, Granich R.

Lancet Infect Dis. 2015 Dec;15(12):1492-6. doi: 10.1016/S1473-3099(15)00242-X. Epub 2015 Oct 27. Review.

PMID:
26515525
3.

Evaluation of the isoniazid preventive therapy (IPT) program in Shurugwi District, Midlands Province, Zimbabwe, January 2013 to August 2014.

Makoni A, Chemhuru M, Tshimanga M, Gombe NT, Mungati M, Bangure D.

BMC Res Notes. 2015 Sep 25;8:476. doi: 10.1186/s13104-015-1451-y.

5.

Bioequivalence of fixed-dose combination RIN®-150 to each reference drug in loose combination.

Wang HF, Wang R, O'Gorman M, Crownover P, Damle B.

Int J Tuberc Lung Dis. 2015 Mar;19(3):333-8. doi: 10.5588/ijtld.14.0447.

PMID:
25686143
6.

Comparative bioavailability of rifampicin and isoniazid in fixed-dose combinations and single-drug formulations.

Hao LH, Guo SC, Liu CC, Zhu H, Wang B, Fu L, Chen MT, Zhou L, Chi JY, Yang W, Nie WJ, Lu Y.

Int J Tuberc Lung Dis. 2014 Dec;18(12):1505-12. doi: 10.5588/ijtld.13.0647.

PMID:
25517820
7.

Quality of antiretroviral and opportunistic infection medications dispensed from developing countries and Internet pharmacies.

Wang T, Hoag SW, Eng ML, Polli J, Pandit NS.

J Clin Pharm Ther. 2015 Feb;40(1):68-75. doi: 10.1111/jcpt.12226. Epub 2014 Nov 10.

PMID:
25381836
8.

Experimental study of PLLA/INH slow release implant fabricated by three dimensional printing technique and drug release characteristics in vitro.

Wu G, Wu W, Zheng Q, Li J, Zhou J, Hu Z.

Biomed Eng Online. 2014 Jul 19;13:97. doi: 10.1186/1475-925X-13-97.

9.

Enhanced electrocatalytic oxidation of isoniazid at electrochemically modified rhodium electrode for biological and pharmaceutical analysis.

Cheemalapati S, Chen SM, Ali MA, Al-Hemaid FM.

Colloids Surf B Biointerfaces. 2014 Sep 1;121:444-50. doi: 10.1016/j.colsurfb.2014.06.035. Epub 2014 Jun 21.

PMID:
25023902
10.

Isoniazid, pyrazinamide and rifampicin content variation in split fixed-dose combination tablets.

Pouplin T, Phuong PN, Toi PV, Nguyen Pouplin J, Farrar J.

PLoS One. 2014 Jul 8;9(7):e102047. doi: 10.1371/journal.pone.0102047. eCollection 2014.

11.

Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly With Rifapentine and Isoniazid for Latent Tuberculosis Infection.

Weiner M, Savic RM, Kenzie WR, Wing D, Peloquin CA, Engle M, Bliven E, Prihoda TJ, Gelfond JA, Scott NA, Abdel-Rahman SM, Kearns GL, Burman WJ, Sterling TR, Villarino ME; Tuberculosis Trials Consortium PREVENT TB Pharmacokinetic Group.

J Pediatric Infect Dis Soc. 2014 Jun;3(2):132-45. doi: 10.1093/jpids/pit077. Epub 2014 Jan 16.

12.

Potassium permanganate-acridine yellow chemiluminescence system for the determination of fluvoxamine, isoniazid and ceftriaxone.

Abolhasani J, Hassanzadeh J.

Luminescence. 2014 Dec;29(8):1053-8. doi: 10.1002/bio.2659. Epub 2014 Apr 22.

PMID:
24753178
13.

The Effect of Garcin® in Preventing AntiTB-Induced Hepatitis in Newly Diagnosed Tuberculosis Patients.

Tabarsi P, Fahimi F, Heidarzadeh N, Haghgoo R, Kazempour M, Masjedi M, Velayati AA.

Iran J Pharm Res. 2014 Winter;13(Suppl):169-76.

14.

Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.

Zvada SP, Denti P, Donald PR, Schaaf HS, Thee S, Seddon JA, Seifart HI, Smith PJ, McIlleron HM, Simonsson US.

J Antimicrob Chemother. 2014 May;69(5):1339-49. doi: 10.1093/jac/dkt524. Epub 2014 Jan 31.

15.

Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.

Centers for Disease Control and Prevention.

MMWR Recomm Rep. 2013 Oct 25;62(RR-09):1-12. Erratum in: MMWR Recomm Rep. 2013 Nov 15;62(45):906.

16.

Estimation of content of anti-TB drugs supplied at centres of the Revised National TB Control Programme in Tamil Nadu, India.

Ramachandran G, Chandrasekaran V, Hemanth Kumar AK, Dewan P, Swaminathan S, Thomas A.

Trop Med Int Health. 2013 Sep;18(9):1141-4. doi: 10.1111/tmi.12158.

17.

The pharmacokinetics of enteral antituberculosis drugs in patients requiring intensive care.

Koegelenberg CF, Nortje A, Lalla U, Enslin A, Irusen EM, Rosenkranz B, Seifart HI, Bolliger CT.

S Afr Med J. 2013 Apr 5;103(6):394-8. doi: 10.7196/samj.6344.

PMID:
23725959
18.

Direct compression of chitosan: process and formulation factors to improve powder flow and tablet performance.

Buys GM, du Plessis LH, Marais AF, Kotze AF, Hamman JH.

Curr Drug Deliv. 2013 Jun;10(3):348-56.

PMID:
23545146
20.

Localized surface plasmon resonance of gold nanoparticles as colorimetric probes for determination of Isoniazid in pharmacological formulation.

Zargar B, Hatamie A.

Spectrochim Acta A Mol Biomol Spectrosc. 2013 Apr;106:185-9. doi: 10.1016/j.saa.2013.01.003. Epub 2013 Jan 11.

PMID:
23380146
Items per page

Supplemental Content

Loading ...
Write to the Help Desk